[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Second Affiliated Hospital of Wenzhou Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":634},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,40,67,88,108,135,159,189,213,232,264,284,316,350,374,395,420,446,476,502,524,547,567,588,608],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100638253","correlation-studies-on-human-body-composition-based-on-bioequivalence-or-pharmacokinetic-trials-100638253",false,"NCT07611929","Correlation Studies on Human Body Composition Based on Bioequivalence or Pharmacokinetic Trials","Inclusion Criteria:\n\n1. Participants who have been successfully enrolled in the bioequivalence trials of Progesterone Sustained-release vaginal gel；\n2. Have signed the informed consent form, have a full understanding of the content, process, and risks of this study, and can communicate well with the researchers.\n\nExclusion Criteria:1:\n\n1）Participants who may not be able to complete the study for other reasons or are deemed by the investigator to be unsuitable for participation in this study.","ALL","18 Years","65 Years",{"count":20,"type":21},3000,"ESTIMATED","1 Day","OBSERVATIONAL","The aim of this observational study is to investigate the impact of body composition on the absorption, distribution, and metabolism of drugs. The primary question it seeks to answer is: Does body composition affect the absorption, distribution, and metabolism of drugs? By combining pharmacokinetic parameters and adverse drug reactions, the study will analyze differences in the metabolism of drugs under various body composition conditions.\n\nDuring the Phase I clinical trial, under the guidance of the researchers, subjects will use the non-invasive InBody S10 body composition analyzer to obtain body composition data, including but not limited to inorganic salts, muscle mass, lean body mass, body weight, and body fat percentage.",[26],"Healhty","RECRUITING","2026-05-21",{"date":30,"type":31},"2026-05-28","ACTUAL",{"date":33,"type":31},"2024-10-05",{"date":35,"type":21},"2029-12-31",{"name":37,"class":38},"Second Affiliated Hospital of Wenzhou Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":39},"100625597","effect-of-bright-light-therapy-on-idiopathic-scoliosis-100625597","NCT07424703","Effect of Bright Light Therapy on Idiopathic Scoliosis","Effect of Morning Bright Light Therapy on the Onset and Progression of Idiopathic Scoliosis: A Prospective, Single-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 10 and 15 years.\n2. Classified as evening chronotype based on the reduced Horne-Östberg Morningness-Eveningness Questionnaire (rMEQ), defined as a score \\\u003C 12.\n3. Has undergone radiographic evaluation (standing full-spine X-ray) for idiopathic scoliosis at the initial clinic visit.\n4. Skeletally immature (Risser sign 0-3) with a major Cobb angle \\\u003C 40 degrees at baseline.\n5. Written informed consent\u002Fassent provided by the participant and legal guardian.\n6. Willing and able to comply with the study protocol, including device use and scheduled follow-ups.\n\nExclusion Criteria:\n\n1. Plans to relocate outside the study area within the next 24 months.\n2. Use of medications that may interfere with circadian rhythm within the past 3 months (e.g., lithium, exogenous melatonin, melatonergic antidepressants).\n3. Trans-meridian travel across at least two time zones within the past 3 months or anticipated during the study period.\n4. Presence of any eye disease (e.g., glaucoma, retinal disease, macular degeneration) that could be exacerbated by or interfere with light therapy.\n5. Clinically diagnosed sleep disorder (e.g., narcolepsy, restless legs syndrome) or prominent medical condition known to interfere with sleep continuity and quality (e.g., moderate-to-severe eczema).\n6. Severe chronic health conditions that could confound study outcomes, including but not limited to:\n\n   * Known syndromic, neuromuscular, or congenital musculoskeletal causes of scoliosis.\n   * History of spine surgery or significant spinal trauma.\n   * Spinal tumor.\n   * Leg length discrepancy \\> 20 mm.\n   * Other severe chronic diseases (e.g., poorly controlled diabetes, chronic liver or renal disease, malabsorption syndromes).\n   * Severe obesity (body mass index z-score ≥ 3).","10 Years","15 Years",{"count":50,"type":21},120,"INTERVENTIONAL",[53],"NA","This trial aims to investigate whether morning bright light therapy can reduce the progression rate of idiopathic scoliosis in children and potentially prevent its de novo development.",[56,57,58],"Idiopathic Scoliosis","Eveningness","Delayed Sleep Phase","2026-05-14",{"date":61,"type":31},"2026-05-19",{"date":63,"type":31},"2025-09-01",{"date":65,"type":21},"2028-09-01",{"name":37,"class":38},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":16,"minAge":74,"maxAge":48,"enrollmentInfo":75,"targetDuration":4,"studyType":51,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":39},"100618774","effect-of-vitamin-a-supplementation-on-idiopathic-scoliosis-100618774","NCT07335991","Effect of Vitamin A Supplementation on Idiopathic Scoliosis","Effect of Vitamin A Supplementation on the Onset and Progression of Idiopathic Scoliosis: A Prospective, Single-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 6 and 15 years.\n2. Biochemically confirmed vitamin A deficiency (serum retinol \\\u003C 0.20 mg\u002FL) or insufficiency (serum retinol 0.20-0.29 mg\u002FL).\n3. Has undergone radiographic evaluation (standing full-spine X-ray) for idiopathic scoliosis at the initial clinic visit.\n4. Skeletally immature (Risser sign 0-3) with a major Cobb angle \\\u003C 40 degrees at baseline.\n5. Written informed consent\u002Fassent provided by the participant and legal guardian.\n\nExclusion Criteria:\n\n1. Unwillingness or inability to comply with all study procedures and follow-up visits.\n2. Plans to relocate outside the study area within the next 24 months.\n3. Previous high-dose vitamin A supplementation therapy within the past 12 months.\n4. Clinical signs of severe vitamin A deficiency syndrome (e.g., xerophthalmia, Bitot's spots).\n5. Serum vitamin A level \\> 0.70 mg\u002FL (to avoid risk of hypervitaminosis A).\n6. Severe chronic health conditions that could confound study outcomes, including but not limited to:\n\n   * Known syndromic, neuromuscular, or congenital musculoskeletal causes of scoliosis.\n   * History of spine surgery or significant spinal trauma.\n   * Spinal tumor.\n   * Leg length discrepancy \\> 20 mm.\n   * Other severe chronic diseases (e.g., poorly controlled diabetes, chronic liver or renal disease, malabsorption syndromes).\n   * Severe obesity (body mass index z-score ≥ 3).","6 Years",{"count":76,"type":21},140,[53],"This study aims to investigate whether vitamin A supplementation can influence spinal curve magnitude in idiopathic scoliosis children and potentially prevent its de novo development.",[80,56],"Vitamin A Deficiency",{"date":82,"type":31},"2026-05-15",{"date":84,"type":31},"2025-05-13",{"date":86,"type":21},"2028-06-01",{"name":37,"class":38},{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":16,"minAge":74,"maxAge":48,"enrollmentInfo":95,"targetDuration":4,"studyType":51,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":39},"100618527","effect-of-adenotonsillectomy-on-spinal-curve-magnitude-in-children-with-sleep-disordered-breathing-100618527","NCT07332780","Effect of Adenotonsillectomy on Spinal Curve Magnitude in Children With Sleep-Disordered Breathing","A Randomized Controlled Study of Adenotonsillectomy on Spinal Curve Magnitude in Children With Mild Sleep-Disordered Breathing","Inclusion Criteria:\n\n1. Age between 6 and 15 years.\n2. Diagnosed with mild SDB, defined as: Obstructive Apnea-Hypopnea Index (OAHI) ≤5 events\u002Fhour on a laboratory-based PSG performed within the past 6 months, AND parental report of habitual obstructive breathing symptoms (e.g., snoring, mouth-breathing, witnessed apneas) occurring \\>3 nights per week on average.\n3. Tonsillar hypertrophy grade ≥2 (on a scale of 0-4) and deemed an appropriate candidate for AT upon ENT evaluation (i.e., no absolute contraindications such as submucous cleft palate).\n4. Has undergone radiographic screening for idiopathic scoliosis at the first clinic visit.\n5. Skeletally immature (Risser sign 0-3) with spinal Cobb angle \\\u003C 40 degrees.\n6. Informed consent\u002Fassent provided by the participant and guardian.\n\nExclusion Criteria:\n\n1. Unwillingness or inability to comply with study procedures.\n2. Plans to relocate outside the study area within 24 months.\n3. Previous tonsillectomy or adenoidectomy.\n4. Recurrent tonsillitis meeting guideline criteria for immediate AT.\n5. Severe OSA (OAHI \\>10 or as per clinician judgment) or significant hypoxemia requiring immediate CPAP therapy.\n6. Severe chronic conditions that could confound outcomes, including but not limited to:\n\n   * Known syndromic, neuromuscular, or congenital musculoskeletal causes of scoliosis.\n   * History of spine surgery or significant spinal injury.\n   * Spinal tumor.\n   * Leg length discrepancy \\>20 mm.\n   * Severe cardiopulmonary disease (e.g., cystic fibrosis, congenital heart disease).\n   * Significant cardiac arrhythmia noted on PSG.\n   * Bleeding disorders, Sickle Cell Disease.\n   * Uncontrolled diabetes, narcolepsy, or asthma.\n   * Known genetic, craniofacial, neurological, or psychiatric conditions likely to affect the airway or study participation.\n   * Severe obesity (BMI z-score ≥ 3).",{"count":96,"type":21},160,[53],"This study aims to determine the effect of adenotonsillectomy (AT) surgery on the progression of spinal curvature in children with mild sleep-disordered breathing (SDB) and concurrent scoliosis, as well as its potential role in preventing the de novo development of scoliosis in children with SDB.",[100,56,101],"Sleep-disordered Breathing (SDB)","Obstructive Sleep Apnea (OSA)",{"date":82,"type":31},{"date":104,"type":31},"2025-07-11",{"date":106,"type":21},"2028-07-31",{"name":37,"class":38},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100635529","comparative-study-on-the-medium--and-long-term-benefits-of-prosthesis-selection-in-total-knee-arthroplasty-100635529","NCT07553871","Comparative Study on the Medium- and Long-term Benefits of Prosthesis Selection in Total Knee Arthroplasty","Inclusion Criteria:\n\n* Age \\>= 18 years.\n* Diagnosis of end-stage knee osteoarthritis, rheumatoid arthritis, or other conditions meeting the indication for TKA.\n* First-time unilateral knee arthroplasty.\n* Complete medical records, including perioperative records, prosthesis model records, detailed cost information, and regular postoperative follow-up records.\n\nExclusion Criteria:\n\n* Revision knee arthroplasty, simultaneous bilateral arthroplasty, or concomitant arthroplasty of other joints.\n* Arthroplasty performed for non-degenerative conditions such as tumour or acute trauma.\n* Perioperative death or loss to follow-up.\n* Severely incomplete clinical data that preclude valid analysis.",{"count":115,"type":21},3500,"This retrospective real-world study aims to compare the medium- and long-term clinical outcomes, safety, and economic benefits of different knee prosthesis brands used in primary unilateral total knee arthroplasty (TKA) at our hospital. The study will include adult patients who underwent first-time unilateral TKA between January 1, 2022 and December 31, 2025. Outcomes such as postoperative knee function, complications, length of hospital stay, quality of life, and medical costs will be evaluated. The results are expected to provide evidence to support prosthesis selection and optimize healthcare resource allocation.",[118,119],"Knee Osteoarthritis","Rheumatoid Arthritis (RA)",[121,122,123,124,125],"Total Knee Arthroplasty","TKA","Cost-Effectiveness","Prosthesis Selection","Real-World Study","NOT_YET_RECRUITING","2026-04-20",{"date":129,"type":31},"2026-04-28",{"date":131,"type":21},"2026-05-31",{"date":133,"type":21},"2030-12",{"name":37,"class":38},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":39},"100633758","perioperative-pharmacokinetics-of-anesthetic-drugs-and-complications-in-overweight-and-obese-patients-100633758","NCT07530848","Perioperative Pharmacokinetics of Anesthetic Drugs and Complications in Overweight and Obese Patients","Perioperative Pharmacokinetics of Anesthetic Drugs and Complications in Overweight and Obese Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Aged 18-65 years with ASA physical status I-III\n2. Participants were divided into a normal control group (18.5 \\\u003C BMI \\\u003C 23.9 kg\u002Fm²) and an experimental group (BMI \\> 24 kg\u002Fm²)\n3. Voluntary participation with written informed consent approved by the Ethics Committee\n4. No cognitive or verbal communication impairments, with the ability to fully cooperate with the study procedures\n\nExclusion Criteria:\n\n* 1: Severe organ dysfunction, including severe hepatic or renal insufficiency, unstable coronary syndrome, uncontrolled hypertension, and other severe cardiovascular diseases\n\n  2: History of chronic pain or long-term use of opioids\u002Fsedatives; preoperative use of potent CYP3A inhibitors or inducers\n\n  3: Contraindications to body composition measurement via Bioelectrical Impedance Analysis (BIA), including abdominal wall stoma, massive ascites, limb amputation\u002Fabsence, and presence of cardiac pacemakers or implantable cardioverter-defibrillators (ICDs)\n\n  4: Women who were pregnant or breastfeeding were excluded from the study\n\n  5: Known hypersensitivity or allergy to study medications\n\n  6: Any other condition deemed by the investigator to make the patient unsuitable for participation, including but not limited to severe psychiatric disorders or legal restrictions",{"count":143,"type":21},2100,"This observational study aims to investigate the impact of body composition on the absorption, distribution, and metabolism of anesthetic drugs, as well as on the incidence of complications in overweight and obese patients. The primary research question is whether specific body composition parameters in this population influence drug pharmacokinetics and complication rates. By integrating pharmacokinetic parameters, adverse drug reactions (ADRs), and clinical complications, the study will analyze variations in sufentanil kinetics under different body composition conditions. Under the guidance of research personnel, participants will undergo non-invasive body composition assessment using the nBody S10 analyzer. Key metrics collected will include, but are not limited to, mineral content, muscle mass, lean body mass (LBM), total body weight, and body fat percentage (BFP).",[146,147],"Obesity","Overweight",[146,147,149,150],"Pharmacokinetics","Complications","2026-04-08",{"date":153,"type":31},"2026-04-15",{"date":155,"type":21},"2026-04-10",{"date":157,"type":21},"2028-04-30",{"name":37,"class":38},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":166,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":169,"studyType":23,"phases":4,"briefSummary":170,"conditions":171,"keywords":177,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":39},"100617141","elderly-patients-undergoing-surgery-during-perioperative-period-100617141","NCT07314762","Elderly Patients Undergoing Surgery During Perioperative Period","Elderly Patients Undergoing Surgery During Perioperative Period: a Prospective Cohort Study","Inclusion Criteria:\n\n1\\) Surgical patients aged 65 or above or non-surgical subjects aged 65 or above. 2) Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1）Refused to participate in the study.",true,{"count":168,"type":21},1200,"1 Year","The elderly patients have poorer overall conditions and have lower tolerance to trauma, anesthesia, and surgery. Therefore, the incidence of postoperative complications is relatively higher. In non-cardiac surgeries, approximately 20% of elderly patients experience postoperative complications, and the incidence of postoperative delirium (POD) is 23.8%. This may lead to prolonged hospital stays, increased hospital costs, and affect prognosis and even mortality. The investigators plan to conduct a prospective cohort study by systematically collecting biological samples and clinical information of elderly patients during the perioperative period to explore the possible risk factors and pathogenesis of postoperative delirium and postoperative complications in elderly surgical patients, and to construct a risk prediction model for postoperative complications.",[172,173,174,175,176],"Postoperative Complications","Elderly","Postoperative Delirium (POD)","Risk Prediction Model","Pathogenesis",[178,179,180],"postoperative delirium","elderly","Cohort study","2026-03-26",{"date":183,"type":31},"2026-04-01",{"date":185,"type":31},"2023-12-30",{"date":187,"type":21},"2030-12-30",{"name":37,"class":38},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":166,"sex":197,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":39},"100628648","basic-and-clinical-research-of-pregnancy-induced-hypertension-100628648","NCT07464379","Basic and Clinical Research of Pregnancy-Induced Hypertension","Collect Blood Pressure, Blood, Amniotic Fluid, Placenta and Other Samples From Normal Pregnant Women, Patients With Pregnancy-induced Hypertension and Those Who Have Experienced Miscarriage, and Conduct Tests on Them.","BCRPIH","Inclusion Criteria:\n\n\\- Healthy pregnant women, patients with miscarriage, etc.\n\nExclusion Criteria:\n\n* Heart disease, infections, etc. in pregnant women Uncooperative patients","FEMALE","20 Years","50 Years",{"count":201,"type":21},100,"Collect blood pressure, blood, amniotic fluid, placenta and other samples from normal pregnant women, patients with pregnancy-induced hypertension and those who have experienced miscarriage, and conduct tests on them.",[204],"Pregnancy-induced Hypertension","2026-03-10",{"date":207,"type":31},"2026-03-11",{"date":209,"type":31},"2020-01-01",{"date":211,"type":21},"2028-12-31",{"name":37,"class":38},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":16,"minAge":74,"maxAge":48,"enrollmentInfo":220,"targetDuration":4,"studyType":51,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":39},"100628812","effect-of-bifidobacterium-breve-supplementation-on-the-onset-and-progression-of-idiopathic-scoliosis-100628812","NCT07466511","Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis","Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis: A Prospective, Single-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 6 to 15 years\n\nDiagnosed with idiopathic scoliosis based on clinical evaluation and radiographic examination at the first clinic visit\n\nSkeletally immature, defined as Risser sign 0 to 3\n\nMajor Cobb angle \\\u003C 40 degrees at baseline\n\nWritten informed consent provided by the participant or legal guardian\n\nAble and willing to comply with study procedures\n\nExclusion Criteria:\n\n* Plans to relocate within the next 24 months\n\nUse of antibiotics, probiotics, hormones, immunosuppressants, or other nutritional supplements known to affect gut microbiota within the past 3 months or during the study period without investigator approval\n\nKnown allergy, sensitivity, or intolerance to the investigational product or its ingredients\n\nCurrent or prior significant gastrointestinal disease requiring medication, or history of gastrointestinal surgery\n\nSevere gastrointestinal symptoms such as persistent heartburn or indigestion\n\nMusculoskeletal, neurodevelopmental, syndromic, or other conditions that may account for the spinal deformity\n\nHistory of spine surgery or major spinal injury\n\nSpinal tumor or malignant disease involving the spine\n\nLeg length discrepancy \\> 20 mm\n\nSevere chronic diseases that could interfere with study participation or outcome assessment, including but not limited to diabetes, narcolepsy, or poorly controlled asthma\n\nSevere obesity, defined as BMI z-score ≥ 3",{"count":201,"type":21},[53],"Researchers hypothesized that Bifidobacterium breve Supplement could reduce the progression rate of idiopathic scoliosis in children and potentially prevent the occurrence of new cases of scoliosis.",[56],"2026-03-09",{"date":226,"type":31},"2026-03-12",{"date":228,"type":21},"2027-01-01",{"date":230,"type":21},"2030-12-31",{"name":37,"class":38},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":239,"enrollmentInfo":240,"targetDuration":242,"studyType":23,"phases":4,"briefSummary":243,"conditions":244,"keywords":249,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100620157","mechanisms-of-prognostic-regulation-andprecision-phenotype-ldentification-in-severe-infections-driven-by-specializedpro-resolving-mediators-100620157","NCT07353970","Mechanisms of Prognostic Regulation andPrecision Phenotype Ldentification in Severe Infections Driven by SpecializedPro-Resolving Mediators","MPR-PPI-SPMs","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admission to the intensive care unit (ICU)\n* Diagnosis of severe infection or sepsis, as determined by the treating physician according to current clinical criteria\n* Ability to obtain blood samples as part of routine clinical care within 24-48 hours after ICU admission\n* Informed consent provided by the patient or legally authorized representative (when applicable)\n\nExclusion Criteria:\n\n* Known pregnancy\n* Known immunosuppressive disease (e.g., hematologic malignancy, advanced HIV infection)\n* Use of long-term immunosuppressive therapy or systemic corticosteroids prior to ICU admission\n* Pre-existing end-stage disease with expected survival \\\u003C 28 days (e.g., end-stage cancer receiving palliative care)\n* Enrollment in interventional clinical trials that may influence immune or inflammatory responses\n* Refusal of informed consent by the patient or legal representative\n* Patients in whom blood sampling or follow-up is not feasible (e.g., expected transfer, withdrawal of life-sustaining treatment within 24 hours)","100 Years",{"count":241,"type":21},300,"28 Days","This is a prospective observational study involving adult patients with severe infection who are admitted to the intensive care unit (ICU). Severe infection and sepsis are major causes of death worldwide. Many patients experience uncontrolled inflammation or immune suppression, but current tests are limited in identifying which patients are at highest risk.\n\nThis study focuses on specialized pro-resolving mediators (SPMs), a group of naturally occurring lipid molecules that help the body turn off inflammation and promote healing. Blood samples that are collected during routine clinical care will be used to measure levels of SPMs. No additional blood draws or experimental treatments will be performed.\n\nThe purpose of this study is to understand how SPM levels change over time in patients with severe infection and how these changes relate to organ function and outcomes such as survival. By combining SPM measurements with routine laboratory results, immune cell counts, and imaging findings, the study aims to identify different clinical phenotypes and to develop tools that may help doctors recognize high-risk patients earlier in the future.\n\nAll participants will receive standard medical care determined by their treating physicians. No experimental drugs or interventions are given as part of this study.",[245,246,247,248],"Sepsis","Severe Infection","Multiple Organ Dysfunction Syndrome","Critical Illness",[250,251,252,253,254,255],"Specialized pro-resolving mediators","SPM","Resolvin D1","Immune resolution","Inflammation resolution","Critical care","2026-01-19",{"date":258,"type":31},"2026-01-21",{"date":260,"type":21},"2026-01-15",{"date":262,"type":21},"2028-01-16",{"name":37,"class":38},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":281,"leadSponsor":283,"locationsCount":4},"100618528","mechanisms-of-precise-immune-cell-phenotyping-and-prognostic-prediction-in-severe-infection-100618528","NCT07332793","Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe Infection","PIC-PSI","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Admission to the intensive care unit (ICU)\n* Diagnosis of severe infection, including sepsis, based on established clinical criteria\n* Enrollment within the early phase of ICU admission\n* Informed consent obtained from the patient or a legally authorized representative\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Pregnancy or breastfeeding\n* Known history of hematologic malignancy or active solid malignancy receiving chemotherapy\n* Known primary immunodeficiency or long-term immunosuppressive therapy prior to ICU admission\n* Human immunodeficiency virus (HIV) infection with severe immunosuppression\n* Previous enrollment in this study\n* Refusal or inability to provide informed consent",{"count":272,"type":21},200,"The goal of this observational study is to learn how changes in immune cells are linked to outcomes in adults with severe infection who are treated in the intensive care unit (ICU). Severe infections, including sepsis, can affect how the immune system works and may lead to poor recovery or death. Researchers want to better understand these immune changes so that people at higher risk can be identified earlier.\n\nThe main questions this study aims to answer are:\n\nAre certain immune cell patterns linked to survival or death within 28 days? Are these immune patterns linked to organ failure or longer stays in the ICU? Participants will be adults with severe infection who are admitted to the ICU as part of their routine medical care. This study does not change or add to their medical treatment.\n\nParticipants will:\n\nHave small blood samples collected at several time points during their ICU stay Allow researchers to review their medical records, including test results and outcomes Researchers will analyze immune cells in the blood and relate these findings to clinical outcomes. The results may help improve future risk assessment and understanding of immune changes in people with severe infection.",[245],[276,245],"immune cells","2025-12-31",{"date":279,"type":31},"2026-01-12",{"date":260,"type":21},{"date":282,"type":21},"2028-01-15",{"name":37,"class":38},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":16,"minAge":291,"maxAge":74,"enrollmentInfo":292,"targetDuration":4,"studyType":51,"phases":294,"briefSummary":295,"conditions":296,"keywords":302,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":39},"100523211","effect-of-fpca-on-incidence-of-emergency-delirium-in-children-after-surgery-100523211","NCT06092671","Effect of FPCA on Incidence of Emergency Delirium in Children After Surgery","Effect of Family-centred Perioperative Care for Anaesthesia on Incidence of Emergency Delirium in Children After Surgery: a Protocol for a Randomised Controlled Trial","Inclusion criteria:\n\n1. Children aged 2-6 years undergoing elective surgery with an estimated surgical duration of no longer than 2 hours;\n2. Receiving first general anaesthesia by inhalation, and American Society of Anaesthesiology (ASA) physical status I to II;\n3. A parent signed the informed consent form.\n\nExclusion criteria:\n\n1. Suffering important organ diseases;\n2. History of developmental retardation, neuropsychiatric diseases, psychological or cognitive impairment;\n3. History of severe hearing or visual impairment;\n4. Children are not suitable for inhalation anaesthesia considered by the researchers;\n5. The parent involving in this trial spends less than three months a year with the child;\n6. The parent is not competent for companionship considered by the researchers;\n7. Neither father nor mother is able to participate in the screening interview and the trial.","2 Years",{"count":293,"type":21},444,[53],"Emergence delirium (ED) stands out as a prevalent postoperative complication among paediatric patients, correlating with extended hospitalization periods, escalated healthcare expenses, and increased incidence of postoperative maladaptive behaviours (POMBs). There is a lack of well-established pharmacological or non-pharmacological interventions demonstrating efficacy in reducing the occurrence of ED. Therefore, our objective is to assess the potential of family-centred perioperative care for anaesthesia (FPCA) in mitigating the incidence of ED in children, compared with routine anaesthesia.",[172,297,298,299,300,301],"Child","Family","Emergence Delirium","General Anaesthesia","Perioperative Care",[303,304,305,306,307],"perioperative care","emergency delirium","paediatric","general anaesthesia","postoperative maladaptive behaviours","2025-12-21",{"date":310,"type":31},"2025-12-29",{"date":312,"type":31},"2023-10-24",{"date":314,"type":21},"2026-12",{"name":37,"class":38},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":16,"minAge":322,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":51,"phases":326,"briefSummary":328,"conditions":329,"keywords":338,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":349},"100581678","phase-4-determination-of-ed50-and-ed95-with-clinical-efficacy-of-intranasal-dexmedetomidine-combined-with-esketamine-for-preoperative-sedation-in-pediatric-general-anesthesia-100581678","NCT06853431","Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia","Inclusion Criteria:\n\n1. ASA physical status classification Grade I or II;\n2. Age 1-6 years old;\n3. Children who need to undergo general anesthesia for elective surgery;\n4. Weight within the normal range;\n5. Signed informed consent form. -\n\nExclusion Criteria:\n\n1. The child's guardian or the child themselves refuses to participate in the study;\n2. Patients with contraindications for sedation\u002Fanesthesia or a history of abnormal recovery from sedation\u002Fanesthesia;\n3. Individuals known to be allergic to the study drugs, opioid drugs, or rescue medications;\n4. Individuals with a history of heart, brain, liver, kidney, or metabolic diseases;\n5. Individuals with an upper respiratory tract infection within the past two weeks;\n6. Individuals with other diseases that may cause harm to the subject. -","12 Months","72 Months",{"count":325,"type":21},80,[327],"PHASE4","For pediatric patients undergoing general anesthesia, poor anesthesia induction compliance often has adverse effects on individual behavior in the early postoperative period. Dexmedetomidine can reduce the cardiovascular responses and postoperative mental adverse reactions caused by esketamine anesthesia induction \\[6\\]. This study aims to explore the ED50 and ED95 and clinical effects of the combination of dexmedetomidine and esketamine nasal drops for preoperative sedation in children of different ages undergoing general anesthesia, providing a theoretical basis for the combined use of dexmedetomidine and esketamine for preoperative sedation in children undergoing general anesthesia.",[330,331,332,333,334,335,336,337],"Preoperative Anxiety","Preoperative Sedation","Children","Dexmedetomidine","Esketamine","ED95","ED50","Preoperative Sedation of Children",[330,339,332,333,334,335,336,340],"Preoperative sedation","preoperative sedation of children","2025-11-24",{"date":343,"type":31},"2025-12-02",{"date":345,"type":31},"2025-03-01",{"date":347,"type":21},"2025-11-30",{"name":37,"class":38},2,{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":166,"sex":16,"minAge":4,"maxAge":242,"enrollmentInfo":358,"targetDuration":4,"studyType":51,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":373,"locationsCount":4},"100605015","research-on-prevention-early-detection-and-clinical-evaluation-of-intracranial-hemorrhage-in-preterm-infants-100605015","NCT07157020","Research on Prevention, Early Detection, and Clinical Evaluation of Intracranial Hemorrhage in Preterm Infants","A Multi-center and Multidisciplinary Research Project on Prevention, Early Detection, and Clinical Evaluation of Intracranial Hemorrhage in Preterm Infants","ROPEDACEOIHIPI","Inclusion Criteria:\n\n* Gestational age: 23+0 weeks to 36+6 weeks;\n* Post-hemorrhagic hydrocephalus is confirmed by cranial ultrasound or other cranial imaging examinations.\n* No cerebrospinal fluid drainage treatment was received before enrollment.\n\nExclusion Criteria:\n\n* Excluding secondary IVH, including but not limited to congenital malformations, vitamin K1 deficiency, abnormal coagulation function, etc.\n* Excluding hydrocephalus caused by other reasons, including but not limited to infection, congenital malformations, intracranial space-occupying lesions, etc.\n* Treatment before diagnosis of hydrocephalus after intraventricular hemorrhage or suspected presence of central nervous system infection.",{"count":241,"type":21},[53],"1. Establish a reference curve for the lateral ventricular diameter of premature infants and determine the intervention threshold for hydrocephalus after hemorrhage in premature infants based on the reference curve, providing a scientific basis for optimizing clinical intervention.\n2. Apply ultrasound radiomics technology to explore and formulate new standards for imaging diagnosis and treatment; By integrating metabolomics, ultrasound radiomics and clinical data, high-risk individuals for intracranial hemorrhage and their relationship with prognosis can be identified early.\n3. To explore whether advancing the indication for surgical intervention of hydrocephalus in preterm infants after hemorrhage from ventricular index P97+4mm to P97 and whether repeated lumbar puncture and drainage can improve their prognosis, with the aim of clarifying the optimal timing for intervention of hydrocephalus in preterm infants after hemorrhage and optimizing the treatment methods.",[362],"Intraventricular Hemorrhage of Prematurity",[362,364,365,366],"prevention","early detection","clinical evaluation","2025-09-03",{"date":369,"type":31},"2025-09-05",{"date":63,"type":21},{"date":372,"type":21},"2026-12-31",{"name":37,"class":38},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":39},"100589494","a-study-on-the-peripheral-blood-in-patients-with-acute-coronary-syndrome-100589494","NCT06955143","A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome","A Study on Integrated Multi-Omics and Multi-Factor Analysis of Peripheral Blood in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\nFor ACS group STEMI\n\n* cTn\\>99th ULN or CK-MB\\>99th ULN\n* ST-segment elevation with a convex upward morphology\n* in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings.\n\nNSTEMI\n\n* cTn\\>99th ULN or CK-MB\\>99th ULN\n* accompanied by one or more of the following situations: persistent ischemic chest pain; new ST-segment depression or low and inverted T waves; echocardiography showing segmental ventricular wall motion abnormalities; abnormal coronary angiography.\n\nUA\n\n* cTn normal\n* ischemic chest pain with an electrocardiogram showing transient ST-segment depression or flattened and inverted T waves\n* evidence of coronary artery stenosis (e.g., CTA demonstrating ≥ 50% stenosis) For CCS group\n* Clinical Diagnosis Consistent with CCS Categories, meet any one of the following clinical scenarios: Stable Angina Pectoris, Ischemic Cardiomyopathy, Post-ACS Stable Phase, Long-Term CAD Management, Vasospastic or Microvascular Disease, Asymptomatic CAD\n* Laboratory and Imaging Confirmation: Resting ECG without ST-segment elevation or dynamic changes (excluding ACS), cTn normal or stable (no acute myocardial injury), ≥50% luminal stenosis in ≥1 epicardial coronary artery For control group\n* Patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy\n\nExclusion Criteria:\n\n* Lactating or pregnant women\n* Patients with malignant neoplasms\n* Severe hepatic\u002Frenal dysfunction\n* Severe hematological disorders\n* Autoimmune diseases",{"count":382,"type":21},310,"The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are:\n\nThe growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.",[385,386],"Acute Coronary Syndrome","Chronic Coronary Syndrome","2025-07-21",{"date":389,"type":31},"2025-07-25",{"date":391,"type":31},"2025-03-11",{"date":393,"type":21},"2025-12",{"name":37,"class":38},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":166,"sex":16,"minAge":4,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":51,"phases":403,"briefSummary":404,"conditions":405,"keywords":410,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":39},"100595694","effect-of-sevoflurane-on-sweat-threshold-in-children-of-different-ages-100595694","NCT07035782","Effect of Sevoflurane on Sweat Threshold in Children of Different Ages","Inclusion Criteria:\n\n1. Age: 0-12 years old;\n2. American Society of Anesthesiologists physical status I or II;\n3. Weight within the normal range and body-mass index (BMI) for age between the 25th and 85th percentiles;\n4. scheduled elective lower-body surgery under general anesthesia, expected to last at least 1 hour.\n\nExclusion Criteria:\n\n1. The guardian of the child refused to participate in the study;\n2. Operations involving extensive incisions, such as massive debridement or other operations requiring removal of large amounts of tissue;\n3. Contraindications to esophageal temperature probe insertion (e.g., esophageal varices, congenital anomalies);\n4. Thyroid dysfunction or autonomic dysfunction;\n5. Premature infants (≤1 year old).","12 Years",{"count":201,"type":21},[53],"Hypothermia is a common complication in pediatric anesthesia. Hypothermia will prolong the recovery time of anesthesia, and may also lead to increased oxygen consumption, prolonged blood coagulation time, and affect the metabolism of anesthetic drugs and postoperative immune function. Sevoflurane is the most commonly used inhaled anesthetic in children. This study explored the effect of sevoflurane on the sweat threshold of pediatric patients and analyzed the characteristics of body temperature regulation in children of different ages under anesthesia, which will help to understand the mechanism of body temperature regulation in children under anesthesia, and also provide a scientific basis for clinical anesthesia temperature management.",[406,407,408,409],"Child, Only","Temperature Regulation; Disorder","Low Body Temperatures","Sevoflurane",[411,408,409],"Pediatric Anesthesia","2025-06-16",{"date":414,"type":31},"2025-06-25",{"date":416,"type":21},"2025-06",{"date":418,"type":21},"2026-06",{"name":37,"class":38},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":16,"minAge":74,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":429,"conditions":430,"keywords":434,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":39},"100592376","zhejiang-adolescent-spine-and-vision-health-cohort-a-longitudinal-database-analysis-100592376","NCT06992622","Zhejiang Adolescent Spine and Vision Health Cohort: A Longitudinal Database Analysis","Inclusion Criteria:\n\n* Diagnosis of idiopathic scoliosis at their first clinic visit\n* Skeletally immature (Risser Sign 0-3)\n* Cobb angle between 11-40 degrees\n* Age between 6 and 17\n\nExclusion Criteria:\n\n* • Patients with scoliosis other than idiopathic, or with other musculoskeletal or neurodevelopmental conditions that might be responsible for the scoliosis\n\n  * History of previous spine surgery or spinal injury\n  * Tumor or malignant tumor in the spine\n  * Leg length discrepancy more than 20 mm\n  * Previous diagnosis or treatment of SDB more than 6 months ago\n  * Plans to relocate within the next 24 months","17 Years",{"count":428,"type":21},73000,"The aim of study: 1. To investigate the prevalence of scoliosis, other spinal deformities, myopia, and visual impairments in adolescents (aged 6-18) in Zhejiang Province.\n\n2.To track 8-year dynamic changes in spinal curvature and analyze associations between scoliosis, vision disorders, and potential risk factors.\n\n3.To deliver scoliosis health education during screenings.\n\n4.To mitigate scoliosis progression through early detection and intervention.",[431,432,433],"Scoliosis Idiopathic","Myopia","Vision Disorders",[435,436,437],"Adolescent idiopathic scoliosis","Longitudinal progression","Spine-vision comorbidity","2025-05-19",{"date":440,"type":31},"2025-05-28",{"date":442,"type":31},"2024-09-30",{"date":444,"type":21},"2032-12-30",{"name":37,"class":38},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":197,"minAge":17,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":51,"phases":455,"briefSummary":456,"conditions":457,"keywords":465,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":475,"locationsCount":39},"100579755","a-clinical-study-on-the-feasibility-and-safety-of-abdominal-endoscopic-single-port-surgery-system-to-assist-gynecological-day-surgery-100579755","NCT06828419","A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery","Inclusion Criteria:\n\n1. Women aged 18 to 75 years old, with a body mass index (BMI) of no more than 32 kg\u002Fm2;\n2. Conscious, no history of mental illness, accompanied by an adult during the perioperative period;\n3. Educate the subjects, who are willing to undergo day surgery, understand and accept the surgical method and anesthesia method;\n4. Subjects and families understand perioperative care and are willing and able to complete post-discharge care;\n5. Elective surgery, no serious complications affecting the operation and prognosis, aCCI age adjusted comorbidity index 0 points;\n6. According to the adhesion risk scoring system of European Anti-Adhesions in Gynaecology Expert Panel (ANGEL), the adhesion risk was divided into three levels: high, medium and low. Subjects with low risk (0 to 12 points) and abdominal wall scarring and pelvic cavity B-ultrasonography do not indicate obvious pelvic cavity adhesion wiil be included.\n\nExclusion Criteria:\n\n1. Moderate and high-risk patients will be excluded based on ANGEL adhesion risk scoring system;\n2. Subjects with hemorrhagic rupture of ectopic pregnancy and unstable vital signs;\n3. Genital tract infection or in the acute phase of systemic infection;\n4. Subjects on long-term anticoagulant therapy or with coagulation dysfunction;\n5. Subjects have severe heart and lung disease, liver and kidney dysfunction, and cannot tolerate anesthesia;\n6. A history of abdominal or diaphragmatic hernia, abnormal umbilical cord development, or umbilical surgery;\n7. Not willing to undergo endoscopic surgery;\n8. Participated in other drug and device clinical trials within 3 months before surgery.","75 Years",{"count":454,"type":21},63,[53],"In this study, a prospective study is used to select patients who will undergo intra-abdominal endoscopic single-port surgery system for benign gynecological diseases from February 2025 to December 2026 in the Second Affiliated Hospital of Wenzhou Medical University, including hysterectomy, myomectomy, ovarian cyst removal and adnexectomy. The study will perform statistical analysis to evaluate the feasibility and the main factors affecting the safety of intra-abdominal endoscopic single-port surgery system(SR-ENS-600) used in gynecological day surgery.",[458,459,460,461,462,463,464],"Adenopathy","Uterine Fibroids","Ovarian Cysts","Adnexal Mass","Ovarian Diseases","Adnexal Cyst","Adnexal Diseases",[466,467,468],"robotic-assisted laparoscopic single-site surgery (R-LESS)","single-port robot system (SPRS)","day surgery","2025-03-27",{"date":471,"type":31},"2025-04-03",{"date":473,"type":21},"2025-04-10",{"date":372,"type":21},{"name":37,"class":38},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":16,"minAge":452,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":51,"phases":485,"briefSummary":486,"conditions":487,"keywords":492,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":39},"100457884","a-study-of-huperzine-a-injection-in-reducing-postoperative-delirium-in-elderly-patients-undergoing-non-cardiac-surgery-100457884","NCT05242419","A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery","A Multi-center, Randomized, Double-blinded, Placebo-controlled Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery","Inclusion Criteria:\n\n* ≥ 75 years old.\n* Comply with the indication of non-cardiac surgery under general anesthesia.\n* Anesthesia grade of American Society of Anesthesiologist (ASA) as III\\~IV grade.\n* The estimated operation time ≥ 2 hours.\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with impaired renal function (Cr is 1.5 times higher than the upper limit of the normal value of the central laboratory) or abnormal liver function (Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST) are 2 times higher than the upper limit of the normal value of the central laboratory).\n* Patients who are positive for infectious diseases.\n* Patients accompanied with central nervous system injury.\n* Patients with previous history of delirium and epilepsy, long-term use of psychoactive drugs or preoperative assessment of delirium.\n* Patients who involved diseases with drug taboos, bronchial asthma, mechanical intestinal obstruction and urinary tract obstruction, or serious systemic diseases, especially circulatory diseases: such as myocardial infarction, heart failure, angina pectoris, history of sinus bradycardia.\n* Patients who are known to be allergic to narcotic drugs or Huperzine A Injection, or must use drugs that are not compatible with Huperzine An Injection.\n* patients who participated in other clinical trials within 3 months before this study, for any reason, who could not tolerate the test or cooperate with the examination, or who has any aphasia, audio-visual dysfunction, etc.\n* the investigators think that the patients is not suitable to participate in this study.",{"count":484,"type":21},40,[53],"To observe and study the clinical effect of Huperzine A Injection on reducing postoperative delirium in elderly patients undergoing non-cardiac surgery",[488,489,490,491],"Injection","Non-cardiac Surgery","Delirium in Old Age","Post Operative Delirium",[493,178,489,494],"Huperzine A Injection","Elderly Patients",{"date":496,"type":31},"2025-04-02",{"date":498,"type":31},"2022-06-10",{"date":500,"type":21},"2025-12-30",{"name":37,"class":38},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":166,"sex":16,"minAge":509,"maxAge":74,"enrollmentInfo":510,"targetDuration":4,"studyType":51,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":39},"100578813","phase-4-effect-of-propofol-versus-remimazolam-intravenous-anesthesia-on-respiratory-depression-100578813","NCT06816173","Effect of Propofol Versus Remimazolam Intravenous Anesthesia on Respiratory Depression","Effect of Propofol Versus Remimazolam Intravenous Anesthesia Combined With Regional or Caudal Block on Respiratory Depression in Young Children: A Randomized Controlled Clinical Study","Inclusion Criteria:\n\n1. Aged 3-6 years, gender unrestricted;\n2. American Society of Anesthesiologists (ASA) physical status classification of I-II;\n3. Body Mass Index (BMI) between 14 kg\u002Fm² and 25 kg\u002Fm²;\n4. Patients requiring elective surgery that can be completely anesthetized through regional or caudal block;\n5. The child's parent or legal guardian voluntarily participates in this trial and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Children requiring special care or under the supervision of a court or social welfare agency;\n2. Children who have received general anesthesia within 3 months prior to the screening period;\n3. Children with a history of respiratory diseases within the past 2 weeks or those deemed to have difficult airway management: Modified Mallampati score of III or IV;\n4. Children with severe cardiovascular diseases or endocrine system abnormalities;\n5. Children with known psychiatric disorders or cognitive impairments;\n6. Children with abnormal liver function, ALT (alanine aminotransferase) and\u002For AST (aspartate aminotransferase) \\>1.5 times the upper limit of normal; children with total bilirubin exceeding the upper limit of normal; children with abnormal kidney function, creatinine and\u002For blood urea nitrogen higher than the upper limit of normal;\n7. Children known or suspected to be allergic to the study drug or benzodiazepines.","3 Years",{"count":511,"type":21},96,[327],"General anesthesia is the preferred choice for pediatric patients, but the induction of volatile anesthetics via face mask may cause preoperative anxiety and postoperative delirium. Total intravenous anesthesia (TIVA) is more suitable for pediatric patients, as it can effectively alleviate preoperative anxiety, reduce the risk of postoperative delirium and mania, shorten hospital stay, reduce medical burden, and increase parental satisfaction. Propofol, although effective for anesthesia, has drawbacks such as injection pain and respiratory and circulatory suppression. Remimazolam is a novel ultra-short-acting benzodiazepine drug, which has no injection pain, minimal impact on respiration and circulation, and rapid onset and elimination, making it suitable for children. However, research on remimazolam in children is limited. This study aims to compare the effect of propofol and remimazolam intravenous anesthesia combined with regional or caudal block on respiratory depression in preschoolers.",[515],"Respiratory Depression","2025-02-04",{"date":518,"type":31},"2025-02-10",{"date":520,"type":21},"2025-02",{"date":522,"type":21},"2026-02",{"name":37,"class":38},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":16,"minAge":169,"maxAge":401,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":533,"conditions":534,"keywords":538,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":39},"100569781","the-eeg-study-under-remimazolam-anesthesia-in-children-100569781","NCT06698705","The EEG Study Under Remimazolam Anesthesia in Children","Electroencephalogram Study in Children Under Remimazolam Anesthesia - a Prospective,Observational Study","Inclusion Criteria:\n\n1\\. aged 1 years-12 years; 2, with American Society of Anesthesiologists (ASA) physical status I or II; 3, children requiring general anesthesia under remimazolam; 4, parents or legal guardians of children who volunteered to participate in the trial; And signed the informed consent form.\n\nExclusion Criteria:\n\n1. Congenital malformation or other genetic conditions that are thought to affect brain development ;\n2. History of severe heart, brain, liver, kidney and metabolic diseases ;\n3. Premature infants (≤32 weeks);\n4. Upper respiratory tract infection in the last two weeks. -",{"count":532,"type":21},60,"The effect of Remimazolam on brain electrical activity. Previous studies have shown that in healthy male volunteers, EEG changes during Remimazolam infusion are characterized by an initial increase in the beta band and a later increase in the delta band. When monitoring the depth of anesthesia, the commonly used Bispectral Index in clinical practice was originally developed for propofol. Therefore, studies have shown that the correlation between the depth of sedation of benzodiazepines such as midazolam and Bispectral Index is weak. In contrast, the beta wave ratio is considered a more suitable EEG indicator for monitoring the sedative effect of Remimazolam. The above indicates that Remimazolam has a specific pattern of influence on EEG activity, especially in the regulation of anesthesia depth, with unique characteristics.",[535,536,537],"Electroencephalography","Remimazolam","Child Neglect",[535,536,539],"children",{"date":541,"type":31},"2025-02-06",{"date":543,"type":31},"2024-11-22",{"date":545,"type":21},"2025-12-01",{"name":37,"class":38},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":166,"sex":16,"minAge":22,"maxAge":74,"enrollmentInfo":554,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":39},"100560659","the-eeg-study-under-sevoflurane-anesthesia-in-children-100560659","NCT06580028","The EEG Study Under Sevoflurane Anesthesia in Children","Electroencephalogram Study in Children Under Sevoflurane Anesthesia - a Prospective,Observational Study","Inclusion Criteria:\n\n1. aged 1 days#6 years#;\n2. with American Society of Anesthesiologists (ASA) physical status I or II#;\n3. children requiring general anesthesia under sevoflurane;\n4. parents or legal guardians of children who volunteered to participate in the trial; And signed the informed consent form.\n\nExclusion Criteria:\n\n1. Congenital malformation or other genetic conditions that are thought to affect brain development ;\n2. History of severe heart, brain, liver, kidney and metabolic diseases ;\n3. Premature infants (≤32 weeks);\n4. Upper respiratory tract infection in the last two weeks.",{"count":555,"type":21},280,"Sevoflurane is one of the most commonly used volatile anesthetics in children because of its rapid induction, recovery and recovery properties. Clinical studies using noninvasive brain monitoring have shown that general anesthetics and hypnotics generate electroencephalogram (EEG) oscillations in specific spatial tissues that are fundamentally related to the structure and function of neural circuits. Slow-wave-delta (0.1-4 Hz) oscillations were present in children of all ages, and the advantage of frontal α-wave oscillations appeared at approximately 6 months, began to be consistent at 10 months, and persisted at older ages. Another study, which analyzed EEG under sevoflurane general anesthesia in children aged 0-6 months, found that Theta and alpha wave power decreased with a decrease in sevoflurane concentrations in infants between 4 and 6 months of recovery. However, these studies lack detailed characterization of the neural circuit activity associated with anesthesia, especially at specific developmental ages that are highly correlated with brain plasticity. The aim of this study was to explore electroencephalogram (EEG) of children of different ages under sevoflurane general anesthesia (including anesthesia induction, maintenance and recovery) . By analyzing these EEG data in detail, we hope to be able to better understand the EEG characteristics of children of different ages under sevoflurane anesthesia, and thus develop a neurophysiology pediatric anesthesia status monitoring strategy.",[535,409,537],[409,332,559],"Electroencephalogram",{"date":561,"type":31},"2025-02-07",{"date":563,"type":31},"2024-09-04",{"date":565,"type":21},"2026-09",{"name":37,"class":38},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":16,"minAge":169,"maxAge":573,"enrollmentInfo":574,"targetDuration":4,"studyType":51,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":4},"100575140","the-dosage-exploration-study-of-peg-rhgh-for-treating-short-stature-in-prepubertal-and-pubertal-children-100575140","NCT06768411","The Dosage Exploration Study of PEG-rhGH for Treating Short Stature in Prepubertal and Pubertal Children","Inclusion Criteria:\n\n1. Patients with short stature or a genetic target height below 2 standard deviations;\n2. Individuals who are pre-pubertal (Tanner stage I) and pubertal (Tanner stages II-IV).\n3. Legal guardians consenting to participate in the study and signing informed consent forms.\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity reactions to the investigational product or related products;\n2. Presence of severe systemic diseases;\n3. Patients with malignant tumors;\n4. Participation in any other clinical trial and receipt of drug or non-drug interventions within the 3 months prior to screening;\n5. Patients unable to adhere to follow-up or receive treatment as scheduled;\n6. Other circumstances in which the investigator deems the patient unsuitable for inclusion in this clinical trial.","16 Years",{"count":575,"type":21},240,[53],"This study is dedicated to addressing the lack of research on the most effective dosage of long-acting growth hormone for children with short stature. By employing clinical trial design, we are committed to investigating the therapeutic benefits and safety profiles associated with varying doses of long-acting growth hormone. Our ultimate goal is to offer clinicians more precise treatment guidance and assist patients in attaining optimal growth and developmental outcomes.",[579],"Short Stature","2025-01-06",{"date":582,"type":31},"2025-01-10",{"date":584,"type":21},"2025-01-15",{"date":586,"type":21},"2027-06-01",{"name":37,"class":38},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":39},"100572900","individual-treatment-of-ustekinumab-in-perianal-fistulizing-crohns-disease-100572900","NCT06739278","Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease","Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab","Inclusion Criteria:\n\n* Clinical diagnosis of Perianal Fistulizing Crohn's Disease\n* Receive ustekinumab therapy\n\nExclusion Criteria:\n\n* Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs\n* Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.\n* Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.\n* Combined with malignant tumor\n* Clinical data missing ≥30% or no follow-up",{"count":596,"type":21},119,"This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.",[599],"Crohn Disease","2024-12-16",{"date":602,"type":31},"2024-12-18",{"date":604,"type":21},"2024-12-20",{"date":606,"type":21},"2025-01-31",{"name":37,"class":38},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":166,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":51,"phases":618,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":39},"100550828","anesthesia-and-perioperative-neurocognitive-disorders-in-the-elderly-patients-undergoing-hip-fracture-surgery-platform-trial-andes-platform-trial-100550828","NCT06452147","Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)","Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial): A Pragmatic Multi-arm, Adaptive, Open Label, Multicenter Randomized Controlled Platform Trial to Assess the Effect of Different Enhance Anesthesia Technique in Perioperative Neurocognitive Function, as Compared to Standard Anesthesia Care in the Elderly Patients Undergoing Hip Fracture","ANDES platform","Inclusion Criteria:\n\n1. Aged 65 years and older.\n2. Patients with unilateral hip fracture (including femoral neck, femoral head, intertrochanteric and subtrochanteric fractures) are scheduled for surgical treatment.\n3. American Society of Anesthesiologists (ASA) physical status IV or below.\n4. The patients or family members provide written informed consent.\n5. Additional inclusion criteria may pertain to specific interventions and will be described in relevant sub-protocols.\n\nExclusion Criteria:\n\n1. Patients with multiple trauma or fractures (excluding trauma that the researcher judges will not affect the patient's overall recovery, such as simple spinal compression fractures, mild soft tissue contusions, fractures of hands and feet, etc.);\n2. Two or more anesthetic surgeries are required.\n3. Petients with an obvious history of head trauma (such as loss of consciousness for more than 5 minutes, post-traumatic amnesia, etc.);\n4. Patients who the researcher believes are unable to complete the assessment of primary outcome;\n5. Additional exclusion criteria may pertain to specific interventions and will be described in relevant sub-protocols.",{"count":617,"type":21},1860,[53],"Anesthesia and perioperative Neurocognitive Disorders in the Elderly patients undergoing hip fracture Surgery platform trial (ANDES platform trial): A pragmatic multi-arm, adaptive, open label, multicenter randomized controlled platform trial to assess the effect of different enhance anesthesia technique in perioperative neurocognitive function, as compared to standard anesthesia care in the elderly patients undergoing hip fracture",[621,622,623,624,625],"Anesthesia","Hip Fractures","Dementia","Cognitive Impairment","Cognitive Decline","2024-11-07",{"date":628,"type":31},"2024-11-08",{"date":630,"type":31},"2024-06-19",{"date":632,"type":21},"2028-07-30",{"name":37,"class":38},""]